Safety and efficacy of carvedilol in severe heart failure

Journal of Cardiac Failure

Volumn 3, Issue 3, 1997, Pages 173-179

  Cohn, Jay N ^a   Fowler, Michael B ^b   Bristow, Michael R ^c   Colucci, Wilson S ^d,g   Gilbert, Edward M ^e   Kinhal, Vithal ^f   Krueger, Steven K ^d,g   Lejemtel, Thierry ^h   Narahara, Kenneth A ⁱ   Packer, Milton ^j   Young, Sarah T ^k   Holcslaw, Terry L ^k   Lukas, Mary Ann ^k  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f #Pierson Clinic   (United States)

^g Nebraska Heart Institute   (United States)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

ⁱ HARBOR UCLA MEDICAL CENTER   (United States)

^j New York State Psychiat Inst and New York Presbyterian Hospital Columbia University Medical Center   (United States)

^k GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

Beta blocker; Carvedilol; Heart failure; Quality of life

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARVEDILOL; PROPANOLAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLASSIFICATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEMODYNAMICS; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; CARBAZOLES; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 0031230455     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(97)90013-0     Document Type: Article

References (27)

1. Benotti JR, Grossman W, Braunwald E, Davolos DD, Alousi AA: Hemodynamic assessment of amrinone: a new inotropic agent N Engl J Med 1978;299:1373-7
2. Baim DS, McDowell AV, Cherniles J, Monrad ES, Parker JA, Edelson J, Braunwald E, Grossman W: Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure. N Engl J Med 1983;309:748-56
3. Sharma B, Hoback J, Francis GS, Hodges M, Asinger RW, Cohn JN, Taylor CR: Pirbuterol: a new oral sympathomimetic amine for the treatment of congestive heart failure. Am Heart J 1981;102:533-41
4. The German and Austrian Xamoterol Study Group: Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Circulation 1982;66:1262-7
5. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, for the PROMISE Study Research Group: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75
6. The Xamoterol in Severe Heart Failure Study Group: Xamoterol in severe heart failure. Lancet 1990;336:1-6
7. Massie BM, Berk MR, Brozena SC, Elkayam U, Plehn JF, Kukin M, Packer M, Murphy BE, Neuberg GW, Steingart RM, Levine TB, deHaan H, for the FACET investigators: Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Circulation 1993;88:492-501
8. Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M, PROFILE Investigators: Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation 1993;88:I-301 (abstr)
9. O'Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Miller AB, Neuberg GW, Pressler ML, Wertheimer JH, Packer M for the PRAISE Investigators: Effect of amlodipine on mode of death in severe chronic heart failure: the PRAISE Trial. Circulation 1995;92:I-143 (abstr)
10. Cohn JN, Ziesche SM, Loss LE, Anderson GF, V-HeFT Study Group: Effect of felodipine on short-term exercise and neurohormones and long-term mortality in heart failure: results of V-HeFT III. Circulation 1995;92:I-143 (abstr)
11. Rousseau MF, Konstam MA, Benedict CR, Donckier J, Galanti L, Melin J, Kinan D, Ahn S, Ketelslegers J-M, Pouleur H: Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994;73:488-93
12. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, White BG: Effects of vesnarinonc on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-55
13. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I: Beneficial effects of long term beta-blockade in congestive cardiomyopathy. Br Heart J 1980;44:117-33
14. Anderson JL, Gilbert EM, O'Connell JB, Renlund D, Yanowitz F, Murray M, Roskelley M, Mealey P, Volkman K, Deitchmna D, Bristow M: Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1991;17:1373-81
15. CIBIS Investigators and Committees: A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73
16. Waagstein F, Bristow MR, Swedberg K, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6
17. Chidsey CA, Harrison DC, Braunwald E: Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med 1962;267:650-4
18. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the U.S. Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55
19. Rector TS, Kubo SH, Cohn JN: Validity of the Minnesota Living With Heart Failure Questionnaire as a measure of therapeutic response: effects of enalapril and placebo. Am J Cardiol 1993;71:1106-7
20. Rector TS, Cohn JN, with the Pimobendan Multicenter Research Group: Assessment of patient outcome with the Minnesota Living With Heart Failure Questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J 1992; 124:1017-25
21. Gaffney TE, Braunwald E: Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 1962;34:320-4
22. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M: Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506
23. Yue T-L, Cheng H-Y, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G: Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263:92-8
24. Gilbert EM, Anderson JL, Deitchman D: Chronic ß-blocker-vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-bund, randomized study of bucindolol versus placebo. Am J Med 1990;88:223-9
25. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P: Long term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993 1993;21:1094-1100
26. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR: Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25: 1225-31
27. Francis GS, Cohn JN: Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention: reviews. FASEB 1990;4:3068-75